Antibody modified Bovine Serum Albumin microspheres for targeted delivery of anticancer agent Gemcitabine

Olga Grinberg, Aharon Gedanken, Debabrata Mukhopadhyay, Chitta Ranjan Patra

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Inhibition of the EGFR signaling pathway is one of the attractive therapeutic targets for pancreatic cancer as recent studies demonstrated that EGFR is over-expressed in pancreatic cancer. In this article we have demonstrated the design of targeted drug delivery system containing Bovine Serum Albumin (BSA) microspheres as delivery vehicle, gemcitabine as anticancer drug and anti-EGFR (epidermal growth factor receptor) monoclonal antibody as targeting agent. The conjugated BSA microspheres were characterized by several physico-chemical techniques such as scanning electron microscope, optical microscopy, fluorescent microscopy etc. Administration of these BSA microspheres containing gemcitabine and anti-EGFR (BSA-Gem-EGFR) shows significant inhibition of pancreatic cancer cells (AsPC1) compared to the cells treated with only BSA microspheres, BSA with gemcitabine (BSA-Gem), and free gemcitabine. This strategy could be used as a generalized approach for the treatment of pancreatic cancer along with other cancers which overexpress EGFR on cell surface.

Original languageEnglish (US)
Pages (from-to)294-299
Number of pages6
JournalPolymers for Advanced Technologies
Volume24
Issue number3
DOIs
StatePublished - Mar 2013

Fingerprint

gemcitabine
Bovine Serum Albumin
Microspheres
Antibodies
Antineoplastic Agents
Monoclonal antibodies
Optical microscopy
Microscopic examination
Electron microscopes
Epidermal Growth Factor Receptor
Cells
Scanning
Monoclonal Antibodies

Keywords

  • Anti-EGFR monoclonal antibody
  • BSA microspheres
  • Gemcitabine
  • Pancreatic cancer cells (AsPC1)
  • Sonochemistry
  • Targeted drug delivery

ASJC Scopus subject areas

  • Polymers and Plastics

Cite this

Antibody modified Bovine Serum Albumin microspheres for targeted delivery of anticancer agent Gemcitabine. / Grinberg, Olga; Gedanken, Aharon; Mukhopadhyay, Debabrata; Patra, Chitta Ranjan.

In: Polymers for Advanced Technologies, Vol. 24, No. 3, 03.2013, p. 294-299.

Research output: Contribution to journalArticle

@article{5d4d7e87e1af40b58d6a851ce6179354,
title = "Antibody modified Bovine Serum Albumin microspheres for targeted delivery of anticancer agent Gemcitabine",
abstract = "Inhibition of the EGFR signaling pathway is one of the attractive therapeutic targets for pancreatic cancer as recent studies demonstrated that EGFR is over-expressed in pancreatic cancer. In this article we have demonstrated the design of targeted drug delivery system containing Bovine Serum Albumin (BSA) microspheres as delivery vehicle, gemcitabine as anticancer drug and anti-EGFR (epidermal growth factor receptor) monoclonal antibody as targeting agent. The conjugated BSA microspheres were characterized by several physico-chemical techniques such as scanning electron microscope, optical microscopy, fluorescent microscopy etc. Administration of these BSA microspheres containing gemcitabine and anti-EGFR (BSA-Gem-EGFR) shows significant inhibition of pancreatic cancer cells (AsPC1) compared to the cells treated with only BSA microspheres, BSA with gemcitabine (BSA-Gem), and free gemcitabine. This strategy could be used as a generalized approach for the treatment of pancreatic cancer along with other cancers which overexpress EGFR on cell surface.",
keywords = "Anti-EGFR monoclonal antibody, BSA microspheres, Gemcitabine, Pancreatic cancer cells (AsPC1), Sonochemistry, Targeted drug delivery",
author = "Olga Grinberg and Aharon Gedanken and Debabrata Mukhopadhyay and Patra, {Chitta Ranjan}",
year = "2013",
month = "3",
doi = "10.1002/pat.3081",
language = "English (US)",
volume = "24",
pages = "294--299",
journal = "Polymers for Advanced Technologies",
issn = "1042-7147",
publisher = "John Wiley and Sons Ltd",
number = "3",

}

TY - JOUR

T1 - Antibody modified Bovine Serum Albumin microspheres for targeted delivery of anticancer agent Gemcitabine

AU - Grinberg, Olga

AU - Gedanken, Aharon

AU - Mukhopadhyay, Debabrata

AU - Patra, Chitta Ranjan

PY - 2013/3

Y1 - 2013/3

N2 - Inhibition of the EGFR signaling pathway is one of the attractive therapeutic targets for pancreatic cancer as recent studies demonstrated that EGFR is over-expressed in pancreatic cancer. In this article we have demonstrated the design of targeted drug delivery system containing Bovine Serum Albumin (BSA) microspheres as delivery vehicle, gemcitabine as anticancer drug and anti-EGFR (epidermal growth factor receptor) monoclonal antibody as targeting agent. The conjugated BSA microspheres were characterized by several physico-chemical techniques such as scanning electron microscope, optical microscopy, fluorescent microscopy etc. Administration of these BSA microspheres containing gemcitabine and anti-EGFR (BSA-Gem-EGFR) shows significant inhibition of pancreatic cancer cells (AsPC1) compared to the cells treated with only BSA microspheres, BSA with gemcitabine (BSA-Gem), and free gemcitabine. This strategy could be used as a generalized approach for the treatment of pancreatic cancer along with other cancers which overexpress EGFR on cell surface.

AB - Inhibition of the EGFR signaling pathway is one of the attractive therapeutic targets for pancreatic cancer as recent studies demonstrated that EGFR is over-expressed in pancreatic cancer. In this article we have demonstrated the design of targeted drug delivery system containing Bovine Serum Albumin (BSA) microspheres as delivery vehicle, gemcitabine as anticancer drug and anti-EGFR (epidermal growth factor receptor) monoclonal antibody as targeting agent. The conjugated BSA microspheres were characterized by several physico-chemical techniques such as scanning electron microscope, optical microscopy, fluorescent microscopy etc. Administration of these BSA microspheres containing gemcitabine and anti-EGFR (BSA-Gem-EGFR) shows significant inhibition of pancreatic cancer cells (AsPC1) compared to the cells treated with only BSA microspheres, BSA with gemcitabine (BSA-Gem), and free gemcitabine. This strategy could be used as a generalized approach for the treatment of pancreatic cancer along with other cancers which overexpress EGFR on cell surface.

KW - Anti-EGFR monoclonal antibody

KW - BSA microspheres

KW - Gemcitabine

KW - Pancreatic cancer cells (AsPC1)

KW - Sonochemistry

KW - Targeted drug delivery

UR - http://www.scopus.com/inward/record.url?scp=84873568015&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873568015&partnerID=8YFLogxK

U2 - 10.1002/pat.3081

DO - 10.1002/pat.3081

M3 - Article

VL - 24

SP - 294

EP - 299

JO - Polymers for Advanced Technologies

JF - Polymers for Advanced Technologies

SN - 1042-7147

IS - 3

ER -